A randomized controlled trial of pegylated-interferon alpha-2b plus ribavirin vs interferon

被引：1
|
作者：
Pol, S [1 ]
Perronne, C [1 ]
Carrat, F [1 ]
Banisadr, F [1 ]
Morand, P [1 ]
Lunel, F [1 ]
Rosenthal, E [1 ]
机构：
[1] ANRS HC02, Paris, France
来源：
JOURNAL OF HEPATOLOGY | 2003年 / 38卷
关键词：
D O I：
10.1016/S0168-8278(03)80508-1
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
92
引用
收藏
页码：32 / 32
页数：1
相关论文
共 50 条
  • [21] Pegylated Interferon Alpha-2b Related Delirium
    Ustun, Cemal
    Ustun, Suzan
    Demir, Caner Feyzi
    KONURALP TIP DERGISI, 2012, 4 (03): : 59 - 61
  • [22] A randomized prospective clinical trial comparing pegylated interferon alpha 2a/ribavirin versus pegylated interferon alpha 2b/ribavirin in the treatment of Chronic Hepatitis C
    Sinha, S
    Gulur, P
    Patel, V
    Hage-Nassar, G
    Tenner, S
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2004, 99 (10): : S77 - S78
  • [23] Effect of Peg Interferon Alpha-2b and Ribavirin dose on the histological changes in virologic non-responders to the combination of standard Interferon alpha-2b and Ribavirin: A randomized controlled study.
    Hassanein, TI
    Barakat, FM
    Myers, WY
    Carlson, MD
    Chatfield, ER
    Selim, KM
    Behling, C
    HEPATOLOGY, 2003, 38 (04) : 742A - 742A
  • [24] Pegylated interferon alpha-2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients
    Callens, S
    Bottieau, E
    Michielsen, P
    Colebunders, R
    AIDS, 2004, 18 (01) : 131 - 131
  • [25] A randomized trial of pegylated interferon α-2b plus ribavirin in the retreatment of chronic hepatitis C
    Jacobson, IM
    Gonzalez, SA
    Ahmed, F
    Lebovics, E
    Min, AD
    Bodenheimer, HC
    Esposito, SP
    Brown, RS
    Bräu, N
    Klion, FM
    Tobias, H
    Bini, EJ
    Brodsky, N
    Cerulli, MA
    Aytaman, A
    Gardner, PW
    Geders, JM
    Spivack, JE
    Rahmin, MG
    Berman, DH
    Ehrlich, J
    Russo, MW
    Chait, M
    Rovner, D
    Edlin, BR
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2005, 100 (11): : 2453 - 2462
  • [26] Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: Some issues
    Yu, Ming-Lung
    Dai, Chia-Yen
    Huang, Jee-Fu
    Hsieh, Ming-Yen
    Chuang, Wan-Long
    HEPATOLOGY, 2008, 47 (05) : 1792 - 1793
  • [27] A randomized controlled trial of pegylated interferon α-2a (40 KD) or interferon α-2a plus ribavirin and amantadine vs interferon α-2a and ribavirin in treatment-naive patients with chronic hepatitis C
    Mangia, A
    Ricci, GL
    Persico, M
    Minerva, N
    Carretta, V
    Bacca, D
    Cela, M
    Piattelli, M
    Annese, M
    Maio, G
    Conte, D
    Guadagnino, V
    Pazienza, V
    Festi, D
    Spirito, F
    Andriulli, A
    JOURNAL OF VIRAL HEPATITIS, 2005, 12 (03) : 292 - 299
  • [28] Acute Hepatitis C: A 24-Week Course of Pegylated Interferon Alpha-2b Versus a 12-Week Course of Pegylated Interferon Alpha-2b Alone or With Ribavirin
    Santantonio, Teresa
    Fasano, Massimo
    Sagnelli, Evangelista
    Tundo, Paolo
    Babudieri, Sergio
    Fabris, Paolo
    Toti, Mario
    Di Perri, Giovanni
    Marino, Nicoletta
    Pizzigallo, Eligio
    Angarano, Gioacchino
    HEPATOLOGY, 2014, 59 (06) : 2101 - 2109
  • [29] Interferon alpha-2b and ribavirin for interferon monotherapy non-responders.
    Herrine, SK
    Conn, MI
    Jefferson, T
    Greenfield, SM
    Shaw, EW
    Thornton, JJ
    Weinberg, DS
    HEPATOLOGY, 1999, 30 (04) : 370A - 370A
  • [30] A 24-Week Pegylated Interferon Alpha-2b Versus a 12-Week Pegylated Interferon Alpha-2b Alone or With Ribavirin for Patients With Acute Hepatitis C Reply
    Dai, Chia-Yen
    Chuang, Wan-Long
    Yu, Ming-Lung
    HEPATOLOGY, 2014, 60 (06) : 2129 - 2129
12345